Cristian Massacesi: Collaboration in Oncology Research Across Brazil
Cristian Massacesi, Chief Medical Officer & Oncology Chief Development Officer at AstraZeneca, posted the following on LinkedIn:
“At AstraZeneca, we are committed to not only delivering medicine to patients in need across the globe, but also investing in the future of medicines globally. A key to doing this successfully is ensuring that the clinical trials we operate are representative of the patients who are intended to be the beneficiaries of an investigational medicine in geographies around the world.
Recently, I had the opportunity to visit some of my AstraZeneca colleagues in Brazil, as well as some key scientific leaders we are collaborating with to conduct more than 60 clinical studies throughout the country in oncology. These studies span some of the most difficult-to-treat cancers today, including lung, head and neck, breast, and hematological cancers, and all combined, these studies have around 600 participants from across Brazil enrolled.
While in Brazil, I was also able to visit the Albert Einstein Hospital in São Paolo where I met with Dr. Gustavo Schvartsman, Dr. Lucila Kerbauy, Dr. Luiz Vicente Rizzo, Dr. Diogo Bugano, and Dr. Guilherme Perini to get a better understanding of the challenges being faced in the Brazilian ecosystem and the importance of continued collaboration across oncology to deliver positive patient outcomes.
I couldn’t be more grateful for the passion I experienced throughout my visit to Brazil. It is a continued inspiration to see so many people committed to a singular goal of improving cancer care. As we rapidly approach the end of 2024, there is so much to be hopeful for in pharmaceutical research, and the dedication and excitement I’ve seen across my visits to research sites throughout the world gives me continued belief in our mission to one day eliminate cancer as a cause of death.”
Dr. Cristian Massacesi, is a medical oncologist with over 20 years of experience in drug development. Currently he serves as the Chief Medical Officer at AstraZeneca. At AstraZeneca, he holds the position of Oncology Chief Development Officer, leading the company’s late-stage Oncology portfolio comprising 13 innovative medicines and immunotherapies. In this role, he directs approximately 150 clinical studies across various indications, concentrating on AstraZeneca’s core disease areas such as breast, lung, gastrointestinal, genitourinary, and gynecological cancers.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023